RSB Spine, LLC, Announces FDA Clearance for Its InterPlate™ C-PS and L-PS Interbody Spacers

Donnerstag, 28. Januar 2010

CLEVELAND – Jan. 28, 2010 – RSB Spine, LLC, today announced that the U.S Food and Drug Administration has approved the company’s 510(k) application to permit the marketing of its InterPlate™ C-PS and L-PS Interbody Spacers.

RSB Spine Chief Executive Officer John A. Redmond said: “We are very excited about this new clearance, since it gives our distributors two additional products to offer customers seeking greater options in Zero-Profile® technologies. Our InterPlate portfolio now provides surgeons with the most unique implant combinations on the market.”

“Zero-Profile technologies comprise one of the fastest growing segments in the spinal industry,” said Mike O’Neill, president of Paradigm BioDevices. “RSB Spine is the only company with a full-line modular interbody platform offering a complete array of material and mechanical loading options that is also code compliant.”

RSB Spine is a privately held medical device company focused on developing innovative spinal implants with a focus on modular fusion products. News releases and other information on the company are available on the Internet at: http://www.rsbspine.com.

CONTACT:

John A. Redmond
Chief Executive Officer
1.866.241.2104

Zero-Profile® is a registered Service Mark of Paradigm BioDevices, Inc., Rockland, MA.